Navigation Links
Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
Date:8/2/2011

SAN FRANCISCO, Aug. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

"This clinical trial in metastatic melanoma provides additional key information for our JX-594 program and complements the ongoing clinical development of JX-594, which is expected to enter a randomized Phase 2b trial in advanced liver cancer later this year," said David Kirn, M.D., president and chief executive officer of Jennerex. "Specifically, JX-594 replication was observed following multiple rounds of intratumoral JX-594 therapy, providing proof-of-concept data for the potential benefit of chronic administration regimens of the product."

The mechanistic proof-of-concept study enrolled 10 treatment-refractory Stage IV melanoma patients, eight of whom completed the study. All patients received up to nine weekly intratumoral injections of JX-594 at a low dose (less than 10 percent of the dose given in other JX-594 trials). Evidence of JX-594 activity was assessed in blood samples and tumor biopsies. Blood samples collected over the course of treatment demonstrated JX-594 replication after repeated dosing as well as the expression and functionality of JX-594 encoded transgenes. Tumor biopsies showed tumor cell necrosis (death) and immune cell recruitment into tumors. JX-594 was safe and well-tolerated, with flu-like symptoms as the most common side effect for patients.

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of act
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
4. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
5. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
6. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
9. Jennerex Closes $5 Million First Tranche of Series C Financing
10. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
11. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... Boston, MA (PRWEB) August 21, 2014 ... collaboration company, has been recognized as one of ... 500 | 5000 magazine for the 2nd consecutive ... on its 33rd annual Inc. 500|5000, an exclusive ... list represents the most comprehensive look at the ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Argenta Advisors(TM), a leading,national life science reimbursement ... joined the team as a medical director for ... leadership of Chief Medical Officer Dr. Brent,O,Connell, guides ... review and payer coverage. Argenta TEC facilitates the,coverage ...
... Its Kind Instant Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, ... a $20 million integrated marketing campaign,for the new TUMS(R) QuikPak(TM), ... TUMS brand. The QuikPak campaign, part of,a larger new "Bring ...
... NVAX ) a clinical-stage vaccine company, announced today that ... presenting at,the World Vaccine Congress 2008 at 11:25 a.m. ... provide an overview of the company,s,strategy, research and development ... Finalist for the Vaccine Industry,Excellence (VIE) Awards 2008 in ...
Cached Biology Technology:Dr. Elizabeth Brown Joins Argenta TEC 2New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2
(Date:8/21/2014)... A study recently published in the journal ... shows a new role for the protein adenomatous polyposis ... cause of cancer-related deaths in the U.S. , Lead ... Molecular Biosciences and co-leader of the Cancer Biology program ... part of her career trying to understand the various ...
(Date:8/21/2014)... An Australian National University (ANU) team has successfully replicated ... way for biological systems powered by sunlight which could ... and so is sunlight. It is an exciting prospect ... cheaply and safely," said Dr Kastoori Hingorani, from the ... ANU Research School of Biology. , Hydrogen offers potential ...
(Date:8/20/2014)... 2014 George E. Fox, a John and Rebecca Moores ... (UH), was named a fellow in the International Society for ... Fox is one of four members two from the ... as fellows in 2014. Fellows are elected every three years, ... 500 members from more than 20 countries, the ISSOL includes ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2
... If something moves where you plan to place your foot ... swinging through. Experts thought previously that if nothing changed in ... your foot will land is fixed before it even leaves ... of immediate visual information during each step. , Researchers monitored ...
... Breeding rice with higher levels of iron can have ... a new study in the Journal of Nutrition. The ... United States, is a major step forward in the ... most debilitating and intractable public health problems affecting nearly ...
... semiconductor crystals, biological probes and a laser, Johns Hopkins ... specific sequences of DNA by making them light up ... the technique will have important uses in medical research, ... sample of DNA containing a mutation linked to ovarian ...
Cached Biology News:Study finds that nutritionally enhanced rice reduces iron deficiency 2Study finds that nutritionally enhanced rice reduces iron deficiency 3New nanosensor uses quantum dots to detect DNA 2
Ready-to-use solution....
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: